KR20230057426A - 종양 미세환경의 유전적 조절을 위한 방법 및 조성물 - Google Patents

종양 미세환경의 유전적 조절을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20230057426A
KR20230057426A KR1020237010117A KR20237010117A KR20230057426A KR 20230057426 A KR20230057426 A KR 20230057426A KR 1020237010117 A KR1020237010117 A KR 1020237010117A KR 20237010117 A KR20237010117 A KR 20237010117A KR 20230057426 A KR20230057426 A KR 20230057426A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitor
formula
compound
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010117A
Other languages
English (en)
Korean (ko)
Inventor
리드 피. 비소네트
로즈마리 엠. 세사리오
로버트 굿나우
파보드 쇼자에이
미릴 길링스
Original Assignee
후야바이오 인터내셔널, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후야바이오 인터내셔널, 엘엘씨 filed Critical 후야바이오 인터내셔널, 엘엘씨
Publication of KR20230057426A publication Critical patent/KR20230057426A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237010117A 2020-08-25 2021-08-24 종양 미세환경의 유전적 조절을 위한 방법 및 조성물 Pending KR20230057426A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070173P 2020-08-25 2020-08-25
US63/070,173 2020-08-25
PCT/US2021/047380 WO2022046792A2 (en) 2020-08-25 2021-08-24 Methods and compositions for genetic modulation of tumor microenvironments

Publications (1)

Publication Number Publication Date
KR20230057426A true KR20230057426A (ko) 2023-04-28

Family

ID=80355668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010117A Pending KR20230057426A (ko) 2020-08-25 2021-08-24 종양 미세환경의 유전적 조절을 위한 방법 및 조성물

Country Status (10)

Country Link
US (1) US20220110924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539246A (cg-RX-API-DMAC7.html)
KR (1) KR20230057426A (cg-RX-API-DMAC7.html)
AU (1) AU2021333655A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190514A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002286A (cg-RX-API-DMAC7.html)
WO (1) WO2022046792A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654979A1 (en) * 2023-01-25 2025-12-03 Huyabio International, LLC Methods and compositions comprising a cardio-tolerated hdac inhibitor
CN117357530A (zh) * 2023-11-07 2024-01-09 苏州大学附属儿童医院 Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Also Published As

Publication number Publication date
EP4203955A2 (en) 2023-07-05
CA3190514A1 (en) 2022-03-03
AU2021333655A9 (en) 2024-06-06
JP2023539246A (ja) 2023-09-13
ZA202302154B (en) 2023-10-25
AU2021333655A1 (en) 2023-05-04
EP4203955A4 (en) 2024-09-18
US20220110924A1 (en) 2022-04-14
WO2022046792A3 (en) 2022-04-07
MX2023002286A (es) 2023-05-16
BR112023003466A2 (pt) 2023-05-09
WO2022046792A2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20250026832A1 (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
KR102471590B1 (ko) Hdac 억제제 및 pd-l1 억제제의 병용 요법
US20220110924A1 (en) Methods and compositions for genetic modulation of tumor microenvironments
US20200383961A1 (en) Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors
US20240252474A1 (en) Methods and compositions comprising a cardio-tolerated hdac inhibitor
HK40129132A (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
EA045229B1 (ru) Комбинация ингибиторов hdac и pd-1 и её применение для лечения рака толстой кишки
HK40008034A (en) Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor
HK40008034B (en) Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor
EA042997B1 (ru) Комбинированная терапия рака ингибитором hdac и ингибитором pd-l1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240823

Comment text: Request for Examination of Application